Nuvation Bio's book value per share for the quarter that ended in Dec. 2023 was $0.00.
During the past 12 months, Nuvation Bio's average Book Value Per Share Growth Rate was -7.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 40.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 4 years, the highest 3-Year average Book Value Per Share Growth Rate of Nuvation Bio was 40.90% per year. The lowest was 40.90% per year. And the median was 40.90% per year.
Nuvation Bio's current price is $0.1825. Its book value per share for the quarter that ended in Dec. 2023 was $0.00. Hence, today's PB Ratio of Nuvation Bio is .
During the past 4 years, the highest P/B Ratio of Nuvation Bio was 1.92. The lowest was 0.00. And the median was 0.00.
Nuvation Bio Book Value per Share Historical Data
The historical data trend for Nuvation Bio's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nuvation Bio's Book Value per Share
For the Biotechnology subindustry, Nuvation Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's PB Ratio falls into.
Nuvation Bio Book Value per Share Calculation
Nuvation Bio's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Nuvation Bio (NYSE:NUVB.WS) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Nuvation Bio Book Value per Share Related Terms
Thank you for viewing the detailed overview of Nuvation Bio's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NUVB.WS has been successfully added to your 